Autres langues NANO MRNA Co.,Ltd.

Actions

4571

JP3651120002

Marché Fermé - Japan Exchange Autres places de cotation 08:00:00 16/07/2024			Varia. 5j.	Varia. 1 janv.
191 ^JPY	-1,55 %		+5,52 %	+0,53 %

2023	NANO MRNA Co. et Kao Corporation concluent un accord de collaboration globale pour la découverte de médicaments à base d'ARNm	CI
2023	NanoCarrier Co. annonce ses résultats pour l'exercice clos le 31 mars 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

NANO MRNA, Kao Tie Up to Develop mRNA Therapies for Allergic Diseases	15/11
NANO MRNA Co., Ltd. and Kao Corporation Agree a Comprehensive Collaborative Research for mRNA Drug Discovery	14/11
NanoCarrier Co., Ltd. announced that it has received ¥13.6793 million in funding from Axcelead Inc., IPGaia, Inc.	12/06/23
NanoCarrier Co., Ltd. announced that it expects to receive ¥13.6793 million in funding from Axcelead Inc., IPGaia, Inc.	26/05/23
NanoCarrier Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	12/05/23
US Patent Office Grants Patrys Two New Deoxymab Patents	18/04/23
NanoCarrier Co., Ltd. announced that it has received Â¥1.11096909 billion in funding from Whiz Partners Inc.	13/02/23
NanoCarrier Co., Ltd. announced that it expects to receive ¥1.11096909 billion in funding from Whiz Partners Inc.	25/01/23
NanoCarrier Co., Ltd. Reports Earnings Results for the Half Year Ended September 30, 2022	11/11/22
InnoCan Pharma Corporation: Innocan Pharma berichtet über weitere Erfolge bei der Profilcharakterisierung von Mikro-RNA in seinem Projekt für eine Verabreichungsplattform für mit Cannabinoiden beladenen Exosomen (CLX)	10/11/21
NanoCarrier : Commences in Domestic Patients Administration of VB-111, a gene therapy product Global Phase III Trial in Platinum-Resistant Ovarian Cancer	10/06/21
NanoCarrier Co., Ltd. Commences in Domestic Patients Administration of VB-111, A Gene Therapy Product Global Phase III Trial in Platinum-Resistant Ovarian Cancer	10/06/21
NanoCarrier Co., Ltd. announced that it expects to receive ¥1.15292206 billion in funding from THE KENKO FUTURE Limited Partnership	23/04/21
Nanocarrier : Concludes NC-6004 Phase III Clinical Study for Pancreatic Cancer	30/11/20
NanoCarrier Announces the Conclusion of NC-6004 Phase III Clinical Study for Pancreatic Cancer	27/11/20
Nanocarrier : Administers Head and Neck Cancer Drug NC-6004 to First Patient	06/11/20
Nanocarrier Co., Ltd. Starts Administering NC-6004 in the Phase IIb Clinical Study in Combination with Keytruda for Head and Neck Cancer	05/11/20
NanoCarrier Presents Favorable Data from Phase IIa Portion of NC-6004 Phase II Clinical Study in Combination with Keytruda	26/10/20
NanoCarrier Co., Ltd. completed the acquisition remaining 92.62% AccuRna, Inc. from Fast Track Initiative No. 2 Investment Business Limited Liability, SMBC Venture Capital Co., Ltd., Innovation Platform Development No. 1 Fund, fund managed by UTokyo Innovation Platform Co., Ltd. and Kazunori Kataoka.	30/09/20
NanoCarrier Co., Ltd. Announces the First Participant Dosed in Investigator-Initiated Phase I Clinical Trial in Patients with Breast Cancer in Japan	03/09/20

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues NANO MRNA Co.,Ltd.

Actions

4571

JP3651120002

Autres langues

Filtres